Timothy P Hughes

Timothy P Hughes

UNVERIFIED PROFILE

Are you Timothy P Hughes?   Register this Author

Register author
Timothy P Hughes

Timothy P Hughes

Publications by authors named "Timothy P Hughes"

Are you Timothy P Hughes?   Register this Author

100Publications

2348Reads

43Profile Views

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Blood 2018 11;132(20):2125-2133

Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-05
Publisher Site
http://dx.doi.org/10.1182/blood-2018-05-848630DOI Listing
November 2018

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):168-176

Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246017PMC
November 2018

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Leukemia 2018 10 23;32(10):2288-2291. Epub 2018 Mar 23.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0101-5DOI Listing
October 2018

Treatment-Free Remission After Second-Line Nilotinib Treatment.

Ann Intern Med 2018 10;169(7):510

South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (T.P.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/L18-0431DOI Listing
October 2018

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

J Clin Oncol 2018 09 31;36(25):2657-2658. Epub 2018 May 31.

David M. Ross, Royal Adelaide Hospital, South Australian Health and Medical Research Institute, and Flinders University and Medical Centre, Adelaide, South Australia, Australia; Kate L. Burbury, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Andrew P. Grigg, Austin Hospital, Melbourne, Victoria, Australia; Timothy P. Hughes, Royal Adelaide Hospital and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; and John F. Seymour, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6137DOI Listing
September 2018

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

Br J Cancer 2018 04 13;118(7):1000-1004. Epub 2018 Mar 13.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0022-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931087PMC
April 2018

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .

Oncotarget 2018 Mar 3;9(17):13423-13437. Epub 2018 Feb 3.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/24393
Publisher Site
http://dx.doi.org/10.18632/oncotarget.24393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862588PMC
March 2018

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Cancer Lett 2017 11 1;408:92-101. Epub 2017 Sep 1.

Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; Australian Genomic Health Alliance, Adelaide, SA, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835173052
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2017.08.034DOI Listing
November 2017

First Approved Kinase Inhibitor for AML.

Cell 2017 Nov;171(5):981

South Australian Health and Medical Research Institute (SAHMRI) and University of Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.11.007DOI Listing
November 2017

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

Cancer Genet 2017 Oct 31;216-217:86-90. Epub 2017 Jul 31.

Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; Australian Genomic Health Alliance, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2017.07.008DOI Listing
October 2017

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

J Mol Diagn 2017 09 18;19(5):711-721. Epub 2017 Jul 18.

Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; Australasian Leukaemia and Lymphoma Group, Melbourne, Victoria, Australia; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia; Department of Molecular Medicine and Pathology, Flinders University and Medical Centre, Adelaide, South Australia, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2017.05.009DOI Listing
September 2017

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Clin Pharmacokinet 2017 08;56(8):977-985

Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, 5005, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0494-0DOI Listing
August 2017

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

PLoS One 2016 18;11(8):e0161470. Epub 2016 Aug 18.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161470PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990177PMC
July 2017

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Leuk Res 2017 04 9;55:55-57. Epub 2017 Jan 9.

Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.01.009DOI Listing
April 2017

Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML.

Nat Rev Clin Oncol 2017 04 7;14(4):201-202. Epub 2017 Feb 7.

Cancer Theme, South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, South Australia 5001, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.11DOI Listing
April 2017

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Blood 2017 03 3;129(9):1166-1176. Epub 2017 Jan 3.

Department of Haematology, SA Pathology, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-745992DOI Listing
March 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.

J Clin Pathol 2016 Sep 2;69(9):817-21. Epub 2016 Feb 2.

Department of Haematology & Genetic Pathology, School of Medicine, Flinders University and Medical Centre, Bedford Park, South Australia, Australia Monoquant Pty Ltd, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2015-203538DOI Listing
September 2016

Moving treatment-free remission into mainstream clinical practice in CML.

Blood 2016 07 24;128(1):17-23. Epub 2016 Mar 24.

Haematology, SA Pathology, School of Medicine, University of Adelaide, Adelaide, Australia; and South Australian Health & Medical Research Institute, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-01-694265DOI Listing
July 2016

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Blood 2016 Apr 14;127(15):1870-80. Epub 2016 Jan 14.

Department of Genetics and Molecular Pathology and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-09-666214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832506PMC
April 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Blood 2015 Dec 23;126(25):2720-3. Epub 2015 Oct 23.

Department of Haematology, SA Pathology, Adelaide, SA, Australia; School of Medicine and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-07-655589DOI Listing
December 2015

Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia.

Int J Hematol 2015 Nov 2;102(5):639-42. Epub 2015 Jul 2.

Department of Haematology, St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC, 3065, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-015-1824-yDOI Listing
November 2015

Living with CML: is death no longer the end (point)?

Blood 2015 Jul;126(1):2-4

SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE; UNIVERSITY OF ADELAIDE; AND SA PATHOLOGY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-644732DOI Listing
July 2015

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia.

J Mol Diagn 2015 Mar 29;17(2):185-92. Epub 2014 Dec 29.

Department of Haematology and Genetic Pathology, School of Medicine, Flinders University and Medical Centre, Bedford Park, South Australia, Australia; Monoquant Pty. Ltd., Adelaide, South Australia, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2014.10.002DOI Listing
March 2015

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Blood 2015 Feb 17;125(6):915-23. Epub 2014 Dec 17.

Department of Haematology, and Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia; Australasian Leukemia and Lymphoma Group, Melbourne, Australia; Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-590315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008PMC
February 2015

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

N Engl J Med 2014 Sep;371(11):1005-15

From the Departments of Pathology (K.G.R., D.P.-T., Y.-L.Y., K. McCastlain, G.S., J.M., S.-C.C., J.C., N.S.-M., I.I., J.W., J.R.D., C.G.M.), Computational Biology and Bioinformatics (Y.L., J.B., M.R., E.H., P.G., P.N., G.W., X.C., J.Z.), Biostatistics (D.P., C.C.), Pharmaceutical Sciences (S.W.P., M.V.R., W.E.E.), and Oncology (C.-H.P., S.J.), the Pediatric Cancer Genome Project (Y.L., L.D., C.L., M.R., J.E., J.C., K.B., R.S.F., E.H., P.G., P.N., G.W., X.C., D.Y., B.V., H.M., M.V.R., W.E.E., E.M., R.K.W., J.R.D., J.Z., C.G.M.), and Cytogenetics Shared Resource (M.V.), St. Jude Children's Research Hospital, Memphis, TN; the University of New Mexico Cancer Center and School of Medicine, Albuquerque (R.C.H., I-M.C., C.L.W.); the Genome Institute at Washington University (L.D., C.L., R.S.F., E.M., R.K.W.), the Department of Genetics, Washington University School of Medicine (L.D., C.L., R.S.F., E.M., R.K.W.), and Siteman Cancer Center, Washington University (E.M., R.K.W.) - all in St. Louis; Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville (M.D.); the Research Institute at Nationwide Children's Hospital (S.R., A.S., J.M.G.-F.), the Department of Pathology, College of Medicine, Ohio State University (N.A.H.), and Ohio State University Comprehensive Cancer Center (G.M., C.D.B., K. Mrózek, J.K.) - all in Columbus, OH; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas (N.J.W.), Scott and White Hospitals and Clinics and Texas A&M Health Science Center, Temple (G.G.), the University of Texas Health Science Center San Antonio, San Antonio (M.F.-J.), and the Departments of Leukemia and Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.M.K., M.K.) - all in Texas; Maine Children's Cancer Program, Scarborough (E.C.L.); New York University Cancer Institute, New York (W.L.C.), and the Department of Medicine (Oncology), Albert Einstein

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1403088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191900PMC
September 2014

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Leuk Lymphoma 2014 Jul 12;55(7):1451-62. Epub 2013 Nov 12.

Department of Leukemia, University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.845883DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186697PMC
July 2014

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

Br J Haematol 2014 Jul 23;166(1):3-11. Epub 2014 Apr 23.

Haematology Directorate, SA Pathology, Adelaide, SA, Australia; School of Medicine, University of Adelaide, Adelaide, SA, Australia; Flinders University and Medical Centre, Bedford Park, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12892DOI Listing
July 2014

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Blood 2014 Jul 23;124(4):511-8. Epub 2014 May 23.

School of Medicine, and Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia; Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-03-566323DOI Listing
July 2014

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Blood 2014 Jul;124(1):153-5

Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, AustraliaSchools of Medicine and Molecular and Biomedical Science, University of Adelaide, Adelaide, AustraliaSchool of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-05-573485DOI Listing
July 2014

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Leuk Lymphoma 2013 Mar 21;54(3):569-78. Epub 2012 Aug 21.

Division of Hematology, SA Pathology, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.715345DOI Listing
March 2013

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

J Clin Endocrinol Metab 2013 Jan 8;98(1):67-76. Epub 2012 Nov 8.

Myeloma Research Laboratory, Division of Hematology, Centre for Cancer Biology, SA Pathology, GPO Box 14, Adelaide, SA, Australia 5000.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2012-2426DOI Listing
January 2013

Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.

Exp Hematol 2012 Aug 19;40(8):612-21.e6. Epub 2012 Apr 19.

Department of Haematology, SA Pathology, RAH Campus, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0301472X1200137
Publisher Site
http://dx.doi.org/10.1016/j.exphem.2012.04.003DOI Listing
August 2012

Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Leuk Lymphoma 2012 Jul 23;53(7):1251-2. Epub 2012 Apr 23.

Haematology Division, SA Pathology, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.682314DOI Listing
July 2012

Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.

Crit Rev Oncog 2012 ;17(1):17-30

Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Australia.

View Article

Download full-text PDF

Source
May 2012

Suboptimal responses in chronic myeloid leukemia: implications and management strategies.

Cancer 2012 Mar 28;118(5):1181-91. Epub 2011 Oct 28.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948PMC
March 2012

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

Blood 2012 Mar 30;119(10):2234-8. Epub 2011 Dec 30.

Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-08-375535DOI Listing
March 2012

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Leuk Lymphoma 2011 Nov 30;52(11):2139-47. Epub 2011 Jun 30.

Department of Haematology, SA Pathology, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.591013DOI Listing
November 2011

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Clin Cancer Res 2011 Nov 8;17(21):6812-21. Epub 2011 Sep 8.

Oncology, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0396DOI Listing
November 2011

Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.

J Clin Oncol 2011 Nov 11;29(32):4250-9. Epub 2011 Oct 11.

SA Pathology, IMVS, e Rd, PO Box 14 Rundle Mall, Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.35.0934DOI Listing
November 2011

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.

Blood 2011 Aug 8;118(6):1622-31. Epub 2011 Jun 8.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-02-33
Publisher Site
http://dx.doi.org/10.1182/blood-2011-02-339267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156048PMC
August 2011

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Curr Hematol Malig Rep 2011 Jun;6(2):88-95

Haematology Department, SA Pathology RAH Site, Frome Road, Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-011-0087-9DOI Listing
June 2011

Mutational analysis in chronic myeloid leukemia: when and what to do?

Curr Opin Hematol 2011 Mar;18(2):111-6

Department of Molecular Pathology, SA Pathology, University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/MOH.0b013e32834399efDOI Listing
March 2011

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Haematologica 2011 Feb 22;96(2):213-20. Epub 2010 Oct 22.

Department of Haematology, SA Pathology (RAH Campus), Frome Road, Adelaide. Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2010.033290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031688PMC
February 2011

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.

Cancer Biol Ther 2010 Oct 1;10(7):715-27. Epub 2010 Oct 1.

Hanson Institute, Adelaide, The University of South Australia, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.10.7.12926DOI Listing
October 2010

Practical considerations for monitoring patients with chronic myeloid leukemia.

Semin Hematol 2010 Oct;47(4):327-34

Department of Molecular Pathology and Centre for Cancer Biology, SA Pathology, School of Medicine, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00371963100008
Publisher Site
http://dx.doi.org/10.1053/j.seminhematol.2010.06.007DOI Listing
October 2010

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

J Clin Endocrinol Metab 2010 Aug 13;95(8):3763-7. Epub 2010 May 13.

Myeloma Research Laboratory, Department of Hematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, G.P.O. Box 14, Adelaide, South Australia 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2010-0086DOI Listing
August 2010

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

J Clin Oncol 2010 Jun 26;28(16):2761-7. Epub 2010 Apr 26.

Haematology Department, Centre for Cancer Biology, SA Pathology (IMVS Campus), University of Adelaide, Frome Road, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.5819DOI Listing
June 2010

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Curr Hematol Malig Rep 2009 Apr;4(2):59-65

Division of Haematology, SA Pathology IMVS/RAH Campus, Frome Road, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-009-0009-2
Publisher Site
http://dx.doi.org/10.1007/s11899-009-0009-2DOI Listing
April 2009